AVITA Medical (NASDAQ:RCEL) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of AVITA Medical (NASDAQ:RCEL) in a research report report published on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock.

RCEL has been the subject of several other reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of AVITA Medical in a research report on Tuesday, December 24th. Piper Sandler reissued a “neutral” rating and set a $12.00 price objective (up from $9.00) on shares of AVITA Medical in a research report on Friday, November 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, AVITA Medical currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

AVITA Medical Price Performance

RCEL stock opened at $8.94 on Wednesday. AVITA Medical has a 1 year low of $7.51 and a 1 year high of $18.93. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.73 and a quick ratio of 3.37. The firm has a market capitalization of $234.39 million, a PE ratio of -4.01 and a beta of 1.58. The business has a 50 day simple moving average of $12.53 and a 200-day simple moving average of $10.59.

AVITA Medical (NASDAQ:RCEL) last issued its earnings results on Thursday, November 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.21). AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.47%. The company had revenue of $19.55 million during the quarter, compared to analyst estimates of $19.65 million. During the same period last year, the business earned ($0.34) earnings per share. Equities research analysts anticipate that AVITA Medical will post -2.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Huntington National Bank acquired a new stake in AVITA Medical in the third quarter valued at approximately $32,000. FMR LLC increased its position in shares of AVITA Medical by 126.9% in the 3rd quarter. FMR LLC now owns 4,248 shares of the company’s stock valued at $46,000 after purchasing an additional 2,376 shares during the last quarter. Quest Partners LLC raised its holdings in shares of AVITA Medical by 269.4% in the 3rd quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock valued at $81,000 after purchasing an additional 5,484 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of AVITA Medical during the 2nd quarter worth $86,000. Finally, IHT Wealth Management LLC grew its stake in shares of AVITA Medical by 24.3% during the third quarter. IHT Wealth Management LLC now owns 28,100 shares of the company’s stock worth $301,000 after purchasing an additional 5,500 shares in the last quarter. 27.66% of the stock is currently owned by institutional investors and hedge funds.

About AVITA Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.